<DOC>
	<DOCNO>NCT00439192</DOCNO>
	<brief_summary>This study design determine efficacy escalate dos ELB245 versus placebo , administer patient OAB compare efficacy escalate dos ELB245 versus standard treatment tolterodine , administer patient OAB .</brief_summary>
	<brief_title>ELB245 12 Weeks Versus 4mg Tolterodine Patients With Incontinent Overactive Bladder ( OAB )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Male female outpatient least 18 year age Symptoms OAB minimum 3 consecutive month prior study entry ; severity OAB ( define patient report symptom ) minimum one month prior study entry Ability use toilet independently without difficulty No treatment medication OAB 4 week prior study entry Written inform consent Breastfeeding woman , pregnant woman woman intend become pregnant study woman childbearing potential sexually active practice highly reliable method birth control Any local pathology , might cause bladder symptom Significant stress urinary incontinence mixed stress/urgency incontinence Any neurological disease affect bladder function muscle strength Patient history lower urinary tract surgery previous pelvic irradiation Local administration botulinum toxin within last 9 month low urinary tract Start change behavioral bladder training program Post void residual volume large 250ml symptom clinically relevant bladder outlet obstruction Nocturial polyuria History liver disease and/or impair liver function Cholestasis Chronic alcohol drug abuse Evidence significantly impair renal function ( Diabetes mellitus ( type I II ) significant peripheral neuropathy and/or polyuria Inflammatory bowel disease Crohn 's disease , ulcerative colitis Uncontrolled narrow angle glaucoma Chronic use carbamazepine paracetamol Participation drug study precede 3 month Concomitant treatment strong CYP3A4 inhibitor History evidence relevant cardiovascular cerebrovascular disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>OAB , proof concept</keyword>
	<keyword>Overactive Bladder ( OAB )</keyword>
	<keyword>incontinence</keyword>
</DOC>